Colorectal cancer is the second leading cause of cancer death worldwide, and the incidence
of this disease is expected to increase as global socioeconomic changes occur. Immune
checkpoint inhibition therapy is effective in treating a minority of colorectal cancer tumors;
however, microsatellite stable tumors do not respond well to this treatment. Emerging cancer
immunotherapeutic strategies aim to activate a cytotoxic T cell response against tumor-
specific antigens, presented exclusively at the cell surface of cancer cells. These antigens …